<https://helda.helsinki.fi>

Synthesis of New Heterocycles from Reactions of 1-Phenyl-1H-pyrazolo[3,4-b]pyridine-5-carbonyl Azides

Aly, Ashraf A.

2019-04

Aly , A A , El-Emary , T I , Mourad , A-F E , Alyan , Z K , Bräse , S & Nieger , M 2019 , '
Synthesis of New Heterocycles from Reactions of
1-Phenyl-1H-pyrazolo[3,4-b]pyridine-5-carbonyl Azides ' , Journal of Heterocyclic Chemistry
, vol. 56 , no. 4 , pp. 1369-1375 . <https://doi.org/10.1002/jhet.3511>

<http://hdl.handle.net/10138/324811>

<https://doi.org/10.1002/jhet.3511>

unspecified

acceptedVersion

Downloaded from Helda, University of Helsinki institutional repository.

This is an electronic reprint of the original article.

This reprint may differ from the original in pagination and typographic detail.

Please cite the original version.

Synthesis of new heterocycles from reactions of 1-phenyl-1H-pyrazolo[3,4-b]pyridine-5-carbonyl azides

Ashraf A Aly,^{a*} Talaat I. El-Emary,^b Aboul-Fetouh E. Mourad,^a Zainab Khallaf Alyan,^a Stefan Bräse,^c and Martin Nieger^d

^a Chemistry Department, Faculty of Science, Minia University, 61519 El-Minia, Egypt

^b Chemistry Department, Faculty of Science, Assiut University, Assiut, Egypt

^c Institute of Organic Chemistry, Karlsruhe Institute of Technology, Fritz-Haber-Weg 6, 76131 Karlsruhe, Germany

^d Department of Chemistry, University of Helsinki, P.O. Box 55, 00014 Helsinki, Finland
Email: ashrafaly63@yahoo.com

Abstract

Two individual examples of pyrazolo[3,4-*b*]pyridinecarbonyl azides and -hydrazides were reacted with various nucleophilic reagents. Different unexpected behavior was observed. NMR, IR, mass spectra together with elemental analyses and X-ray structure analyses were used to prove the structure of the obtained products.

Keywords: Pyrazolo[3,4-*b*]pyridine-5-carbonyl azides, oxazolo[5,4-*b*]pyrazolo[4,3-*e*]pyridin-6-one, pyrazolo[3,4-*b*]pyridinecarbamate, X-ray

Introduction

Among the various heterocyclic systems developed over the last centuries, nitrogen-containing heterocyclic compounds play a crucial role in the context of both chemistry and biology. Pyrazolo[3,4-*b*]pyridines belong to this important class of heterocyclic due to their relevance in medicinal chemistry^{1,2} displayed by the diverse range of biological and pharmaceutical activities such as antitumor,^{3,4} antibacterial,⁵⁻⁷ anti-inflammatory,⁸ inhibitors of protein kinase,⁹ cyclin-dependent kinase 1 (CDK1),¹⁰ glycogen synthase kinase-3 (GSK-3),¹¹ and HIV reverse transcriptase.¹² As an example, a rapid and convenient, environmentally benign synthesis of spiro-pyrazolo[3,4-*b*]pyridine derivatives was developed using a three-component coupling of isatin, cyclic-1,3-dione and pyrazol-5-amine in aqueous ethanol using aluminosilicate nanoparticles as catalyst.¹³ Previously, we also prepared various fused pyridine derivatives *via* the reaction of 2,4(1*H*,3*H*)-quinolinediones with diethyl acetylenedicarboxylate. This reaction furnished ethyl 5,6-dihydro-2,5-dioxo-2*H*-pyrano[3,2-*c*]quinoline-4-carboxylates while 2,4(1*H*,3*H*)-quinolinediones afforded dialkyl 2(4-oxo-1,4-dihydroquinolin-3-yl)fumarates in good yields.¹⁴ Quinoline-2,4-diones were reacted with 2-(2-oxo-1,2-dihydroindol-3-ylidene)-malononitrile in pyridine to yield 2'-amino-2,5'-dioxo-5',6'-dihydrospiro(indoline-3,4'-pyrano[3,2-*c*]quinoline)-3'-carbonitriles in good to excellent yields.¹⁵ In continuation of our work on pyrazolo[3,4-*b*]pyridines,¹⁶⁻²¹ we aim in this work to synthesize fused heterocyclic systems containing pyrazolo[3,4-*b*]pyridine.

Results and Discussion

The pyrazolo[3,4-*b*]pyridines **5** and **8** were prepared by the following sequences: the available 5-aminopyrazole **1** was formylated by the procedure described Häufel et al,²² to give compound **2** (Scheme 1). The spectral data of **2** was reported earlier.²³ Synthesis of pyrazolo[3,4-*b*]pyridine-5-carboxylate (**3**)²³ was also achieved by its reaction with diethyl malonate in glacial acetic acid (Scheme 1).

Scheme 1. Strategy of the synthesis of pyrazolo[3,4-*b*]pyridines **5** and **8**

The reaction of **3** with hydrazine hydrate produced the new compound **4** (Scheme 1). The elemental analysis and mass spectrum of **4** proved its molecular formula as C₁₄H₁₃N₅O₂. The ¹H NMR spectrum of **4** showed the NH₂, NH and CH-pyridine protons at δ = 6.50, 9.40, and 8.10 ppm, respectively. In ¹³C NMR spectrum of **4**, the carbamide and pyridinyl signals appeared at δ = 162.0 and 161.2 ppm, respectively. Reaction of **4** with HNO₂ produced the corresponding 3-methyl-6-oxo-1-phenyl-6,7-dihydro-1*H*-pyrazolo-[3,4-*b*]pyridine-5-carbonyl azide (**5**) (Scheme 1). Analogously, the new compound **8** was established *via* the reaction of **2** with ethyl acetoacetate to give compound **6**²² in 92% yield (Scheme 1). The elemental analysis and mass spectrum of compound **6** corroborated its gross molecular formula as C₁₇H₁₇N₃O₂. The ester protons of **6** appeared in the ¹H NMR as a triplet (3H) and quartet (CH₂) at δ = 1.50 and 4.30 ppm, respectively. The carbonyl ester group resonated in the ¹³C NMR of **6** at δ = 165.0, whereas the three methyl carbon signals were resonated in the ¹³C NMR of **6** at δ = 12.4, 14.3 and 20.1 ppm for the methyl-ester, methyl-pyrazole and methyl-pyridine carbon signals, respectively.

Scheme 2. Suggested mechanism describes the formation of **9**

On subjecting compound **6** with hydrazine hydrate, the reaction proceeded to give compound **7** in 80% yield (Scheme 1). The mass spectrum and elemental analysis of **7** indicated its molecular formula as $C_{15}H_{15}N_5O$ which is supported by the disappearance of ester carbon signals and the appearance of the NH and NH_2 in the IR and 1H NMR spectra were a further support of its structure. When compound **7** was reacted with nitrous acid, the target azide **8** was obtained in a good yield (Scheme 1). IR spectra of both carbonyl azides of pyrazolo[3,4-*b*]pyridines **5** and **8**, showed resonances at $\nu = 2147$ and 2140 cm^{-1} , respectively which are characteristic for CON_3 groups, Besides the disappearance of the bands characteristic for NH and NH_2 groups (see the experimental section) was observed.

Figure 1. Distinctive carbon atoms of compound **9**

Figure 2. Molecular structure of one of the independent molecules of **9** (displacement parameters are drawn at 50% probability level)

Surprisingly, refluxing **5** with methanol for 2 h, a new compound, namely **9** was obtained (Scheme 2). Elemental analysis and mass spectrum proved the molecular formula of **9** as $C_{14}H_{10}N_4O_2$. The 1H NMR spectrum of **9** showed a singlet for NH at $\delta = 12.10$. The pyridine-CH resonates in the 1H NMR spectrum at $\delta = 7.90$. Figure 1 shows distinctive carbon atoms of compound **9**. ^{13}C NMR reveals the carbonyl carbon signal (C-6) at $\delta = 165.0$, whereas CH-pyridine and methyl carbon signal were absorbed at $\delta = 132.0$ (CH-4) and 12.4 (C-a), respectively (detailed spectral data, see the experimental section). The structure of **9** was confirmed by X-ray structure analysis as shown in Figure 2. The mechanism describes the formation of **9** was based upon elimination of N_2 molecule to give intermediate **10**, which was followed by Curtius rearrangement to give the isocyanate **11** (Scheme 2). Nucleophilic addition of the oxygen lone pair of the carbonyl group would form compound **9** (Scheme 2).

In a different manner, reaction of **8** with CH_3OH gave pyrazolo[3,4-*b*]pyridine-5-yl carbamate (**12**) in 80% yield (Scheme 3). The structure of **12** was confirmed by elemental and spectral data. The IR spectrum showed absorption band at $\nu = 1684\text{ cm}^{-1}$ for the carbonyl-ester. Elemental analysis and mass spectrum proved the molecular formula of **12** as $C_{16}H_{16}N_4O_2$. The methyl protons of ester group appeared in the 1H NMR of **12** as a singlet at $\delta = 3.40$ ppm, whereas the carbonyl of the ester group appeared in the ^{13}C NMR spectrum at $\delta = 162.0$ ppm. On reacting compound **8** with hydrazine hydrate in refluxing xylene, the reaction produced

compound **13** (Scheme 3). The same compound **13** was obtained during reaction of **12** with hydrazine hydrate. The ^1H NMR spectrum of **13** revealed the two NH protons at $\delta = 9.10$ and 8.20 ppm. The NH_2 -hydrazine protons appeared together with the aromatic protons at $\delta = 7.24$ - 7.18 ppm. The two methyl protons appeared at $\delta = 2.75$ and 2.50 ppm. Reaction of **8** with acetylacetone yielded 2-acetyl-*N*-(3,6-dimethyl-1-phenyl-1*H*-pyrazolo[3,4-*b*]pyridin-5-yl)-3-oxobutanamide (**14**). The elemental analysis and mass spectrum of **14** indicated a molecular formula as $\text{C}_{20}\text{H}_{20}\text{N}_4\text{O}_3$. The ^1H NMR of compound **14** revealed the CH-proton at $\delta = 4.40$ ppm, whereas the two acetyl protons appeared as one singlet for 6H at $\delta = 2.25$ ppm. In ^{13}C NMR spectrum the carbonyl of the acetyl group appeared at $\delta = 209.0$, whereas the carbonyl of amide carbon appeared at $\delta = 163.0$ ppm. Besides, the aliphatic-CH carbon resonates at $\delta = 96.0$ ppm. On the other site, reaction of carboazide **8** with pyrazolone in boiling xylene gave the pyrazole-4-carboxamide **15** (Scheme 3). Compound **15** was verified by its IR, MS, ^1H NMR, ^{13}C NMR spectra and elemental analysis. Thus, the IR spectrum showed absorption bands at $\delta = 3282\text{ cm}^{-1}$ for NH, 2919 cm^{-1} CH aliphatic, and 1685 - 1680 cm^{-1} for CO groups, respectively. The ^1H NMR spectrum showed three signals at $\delta = 2.20$, 2.60 and 3.40 ppm characteristic for CH_3 pyrazole (A), CH_3 pyrazolone (B) and CH_3 pyridine (C). The $(\text{CH}_3)\text{C}=\text{N}$ carbon signal resonated in the ^{13}C NMR spectrum of **15** at $\delta = 155.2$, whereas the carbonyl carbon signal of pyrazolone at $\delta = 164.0$ ppm (see the Experimental section). The tautomerism of compound **15** (Figure 3) was confirmed by the appearance C-4'' by two values at $\delta = 84.0$ in **15'** and at $\delta = 121.0$ in **15** (Figure 3). The carbon signal assigned to carbonyl amide in **15** appeared at $\delta = 161.0$. In ^1H NMR spectrum, the tautomerism with the NH and OH protons were appeared at $\delta = 8.90$ and 11.00 (Figure 3). The three methyl carbon signals appeared at 17.8 , 15.4 , 14.0 assigned to $(\text{CH}_3\text{-C})$, $(\text{CH}_3\text{-B})$ and $\text{CH}_3\text{-A}$), respectively.

Scheme 3. Reactions of pyrazolo[3,4-*b*]pyridine **8** with various reagents

Figure 3. Distinctive protons and carbons of tautomerism forms of **15** and **15'**

Conclusion

The article reports the reaction of pyrazolo[3,4-*b*]pyridinecarbonylazides and -hydrazides with some nucleophilic reagents. It was observed that of carbonylazide derivative of pyrazolo[3,4-*b*]pyridine-5-

carbonylazide undergo different reaction pathways - a Curtius rearrangement^{27,28} - compared to related compounds. A number of new products were derived from the initial reaction product, an isocyanate.

Experimental Section

General

Melting points were determined using an APP Digital ST 15 melting point apparatus. TLC analyses were performed on analytical Merck 9385 silica aluminum sheets (Kieselgel 60) with PF₂₅₄ indicator. The IR spectra were recorded as KBr disks on Shimadzu-408 infrared spectrophotometer, Faculty of Science, Minia University. The NMR spectra were measured using a Bruker AV-400 spectrometer at the Karlsruhe Institut für Technologie (KIT), Institute of Organic Chemistry, Karlsruhe, Germany. Chemical shifts were expressed as δ (ppm) with tetramethylsilane as internal reference. The samples were dissolved in DMSO-*d*₆, s = singlet, d = doublet, dd = doublet of doublet and t = triplet. Mass spectrometry were recorded on a Varian MAT 312 instrument in EI mode (70 eV), at the Karlsruhe Institut für Technologie (KIT), Institute of Organic Chemistry, Karlsruhe, Germany. Elemental analyses were carried out using Varian Elementary device in National Research Center, Giza, Egypt.

Starting materials

Compound **1** was bought from Aldrich. Compounds **2** and **3** were prepared according to literature procedures.^{22,23}

Compound **2** was obtained as pale yellow crystals in 70 %; mp 98 °C [lit²³ 97.5 °C]; IR (KBr): $\nu_{\max}$ 3350 (NH₂), 3090 (Ar-CH), 1660, (CO), 1615 (C=N), 1590 cm⁻¹ (C=C); ¹H NMR (400 MHz, DMSO-*d*₆): δ = 9.60 (s, 1H, CHO), 7.60-7.50 (m, 5H, Ph-H), 5.80 (bs, 2H, NH₂), 2.30 (s, 3H, CH₃).

On applying the same procedure mentioned in lit.²³, compound **3** was obtained in 75 % yield; mp 286 °C [lit²³ 285 °C]; IR (KBr): $\nu_{\max}$ 3320 (NH₂), 3080 (Ar-CH), 1660, (CO₂Et), 1615 (C=N), 1590 cm⁻¹ (C=C); ¹H NMR (400 MHz, DMSO-*d*₆): δ = 12.20 (s, 1H, NH), 8.20 (s, 1H, pyridine-H), 8.00-7.90 (t, 2H, *J* = 7 Hz, Ph-H), 7.42-7.30 (m, 3H, Ph-H), 4.40 (q, 2H, CH₂), 2.60 (s, 3H, CH₃), 1.40 (t, 3H, *J* = 7.0 Hz, CH₃).

6,7-Dihydro-3-methyl-6-oxo-1-phenyl-1H-pyrazolo[3,4-b]pyridine-5-carbohydrazide (4). A mixture of compound **3** (0.5 g, 1.68 mmol) in hydrazine hydrate (5 mL) was heated under reflux for 5 h. The solution was cooled, poured into ice-cold water containing a few drops of acetic acid, filtered, washed with water, dried and recrystallized from ethanol to give **4** as a yellow powder (0.40 g, 84 %); mp 210 °C; IR (KBr): $\nu_{\max}$ 3340-3315 (NHNH₂), 3070 (Ar-CH), 2970 (Aliph-CH), 1680, 1650 (2CO), 1605 (C=N), 1580 cm⁻¹ (C=C); ¹H NMR (400 MHz, DMSO-*d*₆): δ = 11.50 (s, 1H, NH-pyridine), 9.40 (s, 1H, NH), 8.10 (s, 1H, pyridine-H), 7.05-6.96 (m 5H, Ph-H), 6.50 ppm (s; 2H, NH₂), 2.48 (s, 3H, CH₃); ¹³C NMR (100 MHz, DMSO-*d*₆): δ = 162.0, 161.2 (C=O), 161.3 (C=N), 139.6, 137.0 (Ar-C), 133.0 (Pyridine-CH), 129.8, 126.0 (Ar-C), 127.9, 126.9 (Ar-2CH), 124.0 (Ar-H), 14.4 (CH₃) ppm. MS (70 eV, %): *m/z* 283 (M⁺, 100), 161 (55), 77 (66). Anal Calcd for C₁₄H₁₃N₅O₂ (283.29): Calcd. C, 59.36; H, 4.63; N, 24.72. Found: C, 59.40; H, 4.60; N, 24.90 %.

5-(Azidocarbonyl)-3-methyl-1-phenyl-1H-pyrazolo[3,4-b]pyridin-6(7H)-one (5). A cold solution (0-5 °C) of sodium nitrite (0.319 g, 45 mmol) in 15 mL water was added to a suspension of **4** (0.952 g, 4 mmol) in 1M HCl (2 mL 50%) in an ice bath (0-5 °C) over a period of 30 min. The reaction mixture was left to stir for 1 h at the same temperature and then poured into excess water. The yellow precipitate was filtered off and washed thoroughly with water then dried and left without crystallization to give yellow powder **5** (0.90 g, 80 %) mp. 110 °C; IR (KBr): $\nu_{\max}$ 3100 (Ar-CH), 2950 (Aliph-CH), 2147 (CON₃) and 1632 (C=N) cm⁻¹

Ethyl 3,6-dimethyl-1-phenyl-1H-pyrazolo[3,4-b]pyridine-5-carboxylate (6). A mixture of **2** (0.5 g, 2.48 mmol) and ethyl acetoacetate (0.32 g, 2.48 mmol) in acetic acid (20 mL) was heated under reflux for 24 h. The solution cooled, poured onto ice cold water, filtered, washed with water, dried and recrystallized from ethanol to give white powder **6** (0.67g, 92%); mp 100 °C (lit.²² 101-103 °C); IR (KBr): $\nu_{\max}$ 2921 (Aliph-CH), 1712 cm⁻¹ (CO- ester). ¹H NMR (400 MHz, DMSO-*d*₆): δ = 8.30 (s, 1H, pyridine-H), 7.15-6.95 (m 5H, Ph-H), 4.30 (q, 2H, *J* = 7.0 Hz, CH₂), 2.60 (s, 3H, CH₃), 2.48 (s, 3H, CH₃), 1.50 (t, 3H, *J* = 7.0, CH₃); ¹³C NMR (100 MHz, DMSO-*d*₆): δ = 165.0 (C=O), 163.3, 161.0 (C=N), 139.0, 138.4 (Ar-C), 133.0 (Pyridine-CH), 129.8, 126.0 (Ar-C), 127.9, 126.9 (Ar-2CH), 124.0 (Ar-CH), 62.0 (CH₂-ester), 20.1, 14.3, 12.4 (CH₃) ppm. MS (70 eV, %): *m/z* 295 (M⁺, 100), 161

(55), 77 (66). Anal for $C_{17}H_{17}N_3O_2$ (295.34): Calcd. C, 69.14; H, 5.80; N, 14.23. Found: C, 69.30; H, 5.65; N, 14.10 %.

3,6-Dimethyl-1-phenyl-1H-pyrazolo[3,4-*b*]pyridine-5-carbohydrazide (7). A mixture of the ester **6** (5.90 g, 20 mmol) and hydrazine hydrate (15 mL) was heated under reflux for 7 h. The product that formed was then poured onto cold water, filtered, washed with water, dried and crystallized from ethanol to give buff crystals of **7** (6.09 g, 80%); mp: 170-2 °C; IR (KBr): $\nu_{\max}$ 3428, 3288 (NH₂), 2970 (Aliph-CH), 1680 (CO). ¹H NMR (400 MHz, DMSO-*d*₆): δ = 9.60 (bs, 1H, NH-hydrazine), 8.30 (s, 1H, pyridine-H), 7.40-7.30 (m 5H, Ph-H), 5.90 (bs, 2H, NH₂-hydrazine), 2.56 (s, 3H, CH₃), 2.10 (s, 3H, CH₃); ¹³C NMR (100 MHz, DMSO-*d*₆): δ = 162.3 (C=O), 162.6, 161.4 (C=N), 138.4, 138.0 (Ar-C), 132.6 (Pyridine-CH), 129.4, 126.4 (Ar-C), 128.0, 126.7 (Ar-2CH), 124.2 (Ar-CH), 20.4, 16.1 (CH₃) ppm. MS (70 eV, %): *m/z* 281 (M⁺, 100), 160 (45), 77 (60). Anal for $C_{15}H_{15}N_5O$ (281.32): Calcd. C, 64.04; H, 5.37; N, 24.90. Found: C, 63.90; H, 5.45; N, 25.00 %.

Azido (3,6-dimethyl-1-phenyl-1H-pyrazolo[3,4-*b*]pyridin-5-yl)methanone (8). A cold solution (0-5 °C) of sodium nitrite (0.32 g, 45 mmol) in 15 mL water was added to a suspension of carbohydrazide **7** (1.1 g, 4 mmol) in HCl (2 mL, 50%) in an ice bath (0-5 °C) over a period of 30 min. The reaction mixture was left to stir for 1 h at the same temperature and then poured into excess water. The yellow product was filtered off, washed with water, dried and left without recrystallization to give **8** (0.95 g, 84%); mp 110 °C; IR (KBr): ν = 2140 (CON₃) and 1699 cm⁻¹ (CO).

3-Methyl-1-phenyl-1,5-dihydro-6H-oxazolo[5,4-*b*]pyrazolo[4,3-*e*]pyridin-6-one (9). A mixture of **5** (0.5 g, 1.7 mmol) and methanol (15 mL) was heated under gentle reflux for 2 h. The solution cooled, poured onto ice cold water, filtered, washed with water (100 mL), dried, and recrystallized from ethanol to give **9** (0.33 g, 75%) as yellow crystals; mp 270 °C; IR (KBr): $\nu_{\max}$ 3184 (NH), 3184 (Ar-CH), 2990 (Aliph-CH), 1680 (CO) cm⁻¹; ¹H NMR: (400 MHz, DMSO -*d*₆): δ = 12.10 (s, 1H, NH), 8.10 (dd, 2H, *J* = 7.2, 1.0 Hz, H-c); 7.90 (s, 1H, H-4); 7.30-7.28 (m, 2H, H-b), 7.20 (m, 1H, H-d), 2.50 (s, 3H, CH₃-pyrazole); ¹³C NMR (100 MHz, DMSO-*d*₆): δ = 165.0 (CO), 164.1 (C-7'), 150.2 (C-8'), 143.0 (C-4'), 141.0 (C-e), 138.2 (C-3), 132.0 (C-4), 127.8 (2CH-c), 123.4 (CH-d), 122.0 (2CH-b),

115.0 (C-3'), 12.4 (CH₃-a). MS (70 eV, %): *m/z* 266 (100%). Anal. Calcd. for C₁₄H₁₀N₄O₂ (266.26): C, 63.15; H, 3.79; N, 21.04. Found: C, 63.00; H, 3.70; N, 21.20 %.

Crystal Structure Determination of **9**

The single-crystal X-ray diffraction study was carried out on a Bruker D8 Venture diffractometer with Photon100 detector at 123(2) K using Cu-K α radiation ($\lambda = 1.54178$ Å). Dual space methods [SHELXT]²⁴ were used for structure solution and refinement was carried out using SHELXL-2014 (full-matrix least-squares on F^2)²⁵. Hydrogen atoms were refined using a riding model (H(N)). A semi-empirical absorption correction was applied. Refinement with the listed atoms shows residual electron density due to a heavily disordered ethanol solvent which could not be refined with split atom model. In addition, there are traces of water. Therefore, the option "SQUEEZE" of the program package PLATON²⁶ was used to create a hkl file taking into account the residual electron density in the void areas.

9: Colorless crystals, C₁₄H₁₀N₂O₄ · 1/3(C₂H₆O), $M_r = 281.61$, crystal size 0.20 × 0.18 × 0.08 mm, triclinic, space group *P*-1 (No. 2), $a = 10.6979(3)$ Å, $b = 14.3577(4)$ Å, $c = 14.5395(4)$ Å, $\alpha = 68.818(1)^\circ$, $\beta = 84.428(1)^\circ$, $\gamma = 72.303(1)^\circ$, $V = 1983.60(10)$ Å³, $Z = 6$, $\rho = 1.414$ Mg/m³, $\mu(\text{Cu-K}\alpha) = 0.825$ mm⁻¹, $F(000) = 880$, $2\theta_{\text{max}} = 144.6^\circ$, 30117 reflections, of which 7760 were independent ($R_{\text{int}} = 0.032$), 553 parameters, 3 restraints, $R_1 = 0.041$ (for 6663 $I > 2\sigma(I)$), $wR_2 = 0.108$ (all data), $S = 1.03$, largest diff. peak / hole = 0.384 / -0.218 e Å⁻³.

CCDC 1840903 (**9**) contains the supplementary crystallographic data for this paper. These data can be obtained free of charge from The Cambridge Crystallographic Data Centre via www.ccdc.cam.ac.uk/data_request/cif.

Methyl 3,6-dimethyl-1-phenyl-1H-pyrazolo[3,4-*b*]pyridin-5-yl-carbamate (12**)**. A mixture of **8** (0.29 g, 1 mmol) in methanol (50 mL) was heated under reflux for 10 h. The solution cooled, poured onto ice cold water, filtered, washed with water, dried, and recrystallized from ethanol- water (1:1) to give brown crystals of **12** (0.23 g, 80%); m.p: 180 °C; IR (KBr): ν_{max} 3251 (NH), 3050 (Ar-CH), 2917 (Aliph-CH), 1684 (CO) cm⁻¹; IR (KBr): 3180 (NH), 3180 (Ar-CH), 2890 (Aliph-CH), 1684 (CO) cm⁻¹; ¹H NMR: (400 MHz, DMSO -*d*₆): $\delta = 9.10$ (s, 1H, NH),

7.92 (s, 1H, H-4), 7.30-7.19 (m, 5H, Ar-H), 3.40 (s, 3H, CH₃-ester), 2.60 (s, 3H, CH₃), 2.30 (s, 3H, CH₃); ¹³C NMR (100 MHz, DMSO-d₆): δ = 162.0 (CO), 152.1, 151.20 (C=N), 138.0, 135.0, 133.1, 131.0, 130.0 (Ar-C), 128.2, 127.2 (Ar-2CH), 123.0 (Ar-CH-*p*), 25.4, 20.4, 15.9 ppm (CH₃). MS (70 eV, %): *m/z* 296 (100). Anal. Calcd for C₁₆H₁₆N₄O₂ (296.33): C, 64.85%; H, 5.44; N, 18.91. Found: C, 64.80; H, 5.40; N, 19.00 %.

***N*-(3,6-Dimethyl-1-phenyl-1*H*-pyrazolo[3,4-*b*]pyridine-5-yl)hydrazinecarboxamide (13).** A mixture of methyl carboazide **8** (0.5 g, 1.7 mmol) and hydrazine hydrate (0.85 mL, 1.7 mmol) in xylene (50 mL) was heated under reflux for 11 h. The reaction mixture poured onto petroleum ether, filtered, and washed with petroleum ether, recrystallized from DMF: water (4:1) to give buff crystals of **13** (0.50 g, 81%); m.p 310 °C; IR (KBr): ν_{max} 3230-2150 (NHNH₂), 3020 (Ar-CH), 2860 (Aliph-CH), 1680 (CO) cm⁻¹; ¹H NMR: (400 MHz, DMSO -*d*₆): δ = 9.10 (s, 1*H*, *NH*-hydrazine), 8.20 (s, 1*H*, *NH*), 8.00 (s, 1H, H-4), 7.48-7.44 (m, 2H, Ar-H), 7.24-7.18 (m, 5H, Ar-H, *NH*₂-hydrazine), 2.75 (s, 3H, CH₃), 2.60 (s, 3H, CH₃); ¹³C NMR (100 MHz, DMSO-d₆): δ = 161.0 (CO), 152.4, 151.5 (C=N), 143.0, 140.0 (Ar-C), 133.0 (CH-4), 130.0 (Ar-2CH), 128.8 (Ar-C), 124.0 (Ar-CH), 122.0 (Ar-2CH), 115.4 (Ar-CH-*p*), 25.0, 14.0 ppm (CH₃). MS (70 eV, %): 296 (100). Anal. Calcd for C₁₅H₁₆N₆O (296.33): C, 60.80; H, 5.44; N, 28.36. Found: C, 60.70; H, 5.40; N, 28.40 %.

Reaction of 8 with acetyl acetone; preparation of 2-acetyl-*N*-(3,6-dimethyl-1-phenyl-1*H*-pyrazolo[3,4-*b*]pyridine-5-yl-3-oxobutanamide (14). A mixture of carboazide **8** (0.5 g, 1.7 mmol) and acetylacetone (1.7 mmol) was heated under reflux for 6 h in xylene (20 mL). The reaction mixture poured onto petroleum ether, filtered and washed with petroleum ether. A buff precipitate was recrystallized from DMF: water (4:1) of **14** (0.32 g, 67%); m.p 310 °C; IR (KBr): ν_{max} 3230 (NH), 3010 (Ar-CH), 2870 (Aliph-CH), 1710-1680 (CO) cm⁻¹; ¹H NMR: (400 MHz, DMSO -*d*₆): δ = 8.90 (s, 1*H*, *NH*), 8.10 (s, 1H, H-4), 7.40-7.25 (m, 5H, Ar-H), 4.40 (s, 1H, CH-), 2.50 (s, 3H, CH₃), 2.25 (s, 6H, CH₃), 2.18 (s, 3H, CH₃); ¹³C NMR (100 MHz, DMSO-d₆): δ = 209.0 (2CO), 163.0 (CO), 153.0, 152.0 (C=N), 142.0, 138.0 (Ar-C), 129.7 (Ar-2CH), 128.4 (CH-4), 127.0, 1.26.0 (Ar-C), 119.0 (Ar-2CH), 115.4 (Ar-CH-*p*), 96.0 (CH), 22.4 (2CH₃), 13.2, 12.2 ppm (CH₃). MS (70 eV, %): *m/z* = 364 (100), 263 (65), 237 (80). Anal. Calcd for C₂₀H₂₀N₄O₃ (364.40): C, 65.92; H, 5.53; N, 15.38. Found: C, 65.90; H, 5.50; N, 15.43 %.

N-(3,6-Dimethyl-1-phenyl-1H-pyrazolo[3,4-b]pyridin-5-yl)-3-methyl-5-oxo-1-phenyl-4,5-dihydro-1H-pyrazole-4-carboxamide (15). A mixture of carboazide **8** (0.25 g, 0.85 mmol) and 1-phenyl-3-methyl-5-pyrazolone (0.15 g, 0.86 mmol) was heated in xylene under reflux for 5 h. The reaction mixture was then poured onto petroleum ether, filtered and recrystallized from dioxane to give buff powder **15** (0.28 g, 78%); m.p 330 °C; IR (KBr): $\nu_{\max}$ 3450 (OH), 3282 (NH), 3030 (Ar-CH), 2919 (Aliph-CH), 1680 (CO) cm^{-1} ; ^1H NMR: (400 MHz, DMSO - d_6): δ = 11.0 (s, 1H, OH (NH)), 8.90 (s, 1H, NH (OH)), 8.10 (s, 1H, H-4), 7.50-7.30 (m, 6H, Ar-H), 7.40-7.25 (m, 4H, Ar-H), 3.40 (s, 3H, CH₃-pyrazolone), 2.60 (s, 3H, CH₃-pyrazole), 2.20 (s, 3H, CH₃-pyridine); ^{13}C NMR (100 MHz, DMSO- d_6): δ = 164.0 (CO-pyrazolone), 161.0 (CO-amide), 153.4, 151.2, 150.0 (C=N), 137.7, 135.0, 133.2 (Ar-C), 132.8 (CH-4), 130.6, 130.0 (Ar-C), 128.6, 128.0, 127.6, 126.7 (Ar-2CH), 122.4, 122.2 (Ar-CH-*p*), 121.0 (C-4''), 80.0 (C-4'-pyrazolone), 17.8 (CH₃-C), 15.4 (CH₃-B), 14.0 (CH₃-A)ppm (CH₃). MS (70 eV, %): *m/z* 438 (100), 397 (43), 345 (75), 306 (80), 288 (40). Anal. Calcd for C₂₅H₂₂N₆O₂ (438.49): C, 68.48; H, 5.06; N, 19.17. Found: C, 68.60; H, 5.16; N, 19.30 %.

Acknowledgement

The authors thank 2-MET society for financial support for the accommodation of Prof Ashraf A. Aly at the Institute of Organic Chemistry, Karlsruhe, Germany.

References

- 1 Pagadala, R.; Maddila, S.; Moodley, V.; Vanzyl, V. E.; Jonnalagadda, S. B. *Tetrahedron Lett.* **2014**, *55*, 4006-4010.
DOI: [org/10.1016/j.tetlet.2014.05.089](https://doi.org/10.1016/j.tetlet.2014.05.089)
- 2 Kim, H. S.; Jadhav, J. R.; Jung, S. J.; Kwak, J. H. *Bioorg. Med. Chem. Lett.* **2013**, *23*, 4315-4318.
DOI: [org/10.1016/j.bmcl.2013.05.098](https://doi.org/10.1016/j.bmcl.2013.05.098)
- 3 Lin, R.; Connolly, P. J.; Lu, Y.; Chiu, G.; Li, S.; Yu, Y.; Huang, S.; Li, X.; Emanuel, S. L.; Middleton, S. A.; Gruninger, R. H.; Adams, M.; Fuentes-Pesquera, A. R.; Greenberger, L. M. *Bioorg. Med. Chem. Lett.* **2007**, *17*, 4297-4302.
DOI: [10.1016/j.bmcl.2007.05.029](https://doi.org/10.1016/j.bmcl.2007.05.029)
- 4 Ye, Q.; Cao, J.; Zhou, X.; Lv, D.; He, Q.; Yang, B.; Hu, Y. *Bioorg. Med. Chem.* **2009**, *17*, 4763-4772.
DOI: [org/10.1016/j.bmc.2009.04.043](https://doi.org/10.1016/j.bmc.2009.04.043)
- 5 Leal, B.; Afonso, I. F.; Rodrigues, C. R.; Abreu, P. A.; Garrett, R.; Pinheiro, L. C. S.; Azevedo, A. R.; Borges, J. C.; Vegi, P. F.; Santos, C. C. C.; da Silveira, F. C. A.; Cabral, L. M.; Frugulhetti, I. C. P. P.; Bernardino, A. M. R.; Santos, D. O.; Castro, H. C. *Bioorg. Med. Chem.* **2008**, *16*, 8196-8204.

- DOI: [org/10.1016/j.bmc.2008.07.035](https://doi.org/10.1016/j.bmc.2008.07.035)
- 6 Goda, F. E.; Abdel-Aziz, A. A.-M.; Attef O. A. *Bioorg. Med. Chem.* **2004**, *12*, 1845-1852.
DOI: [org/10.1016/j.bmc.2004.01.040](https://doi.org/10.1016/j.bmc.2004.01.040)
- 7 Foks, H.; Pancechowska-Ksepko, D.; Kudzia, A.; Zwolska, Z.; Janowiec, M.; Augustynowicz-Kopec, E. // *Farmaco* **2005**, *60*, 513-517.
DOI: [10.1016/j.farmac.2005.05.002](https://doi.org/10.1016/j.farmac.2005.05.002)
- 8 Bharate, S. B.; Mahajan, T. R.; Gole, Y. R.; Nambiar, M.; Matan, T. T.; Kulkarni-Almeida, A.; Balachandran, S.; Junjappa, H.; Balakrishnan, A.; Vishwakarma, R. A. *Bioorg. Med. Chem.* **2008**, *16*, 7167-7176.
DOI: [org/10.1016/j.bmc.2008.06.042](https://doi.org/10.1016/j.bmc.2008.06.042)
- 9 Chioua, M.; Samadi, A.; Soriano, E.; Lozach, O.; Meijer, L.; Marco-Contelles, J. *Bioorg. Med. Chem. Lett.* **2009**, *19*, 4566-4569.
DOI: [org/10.1016/j.bmcl.2009.06.099](https://doi.org/10.1016/j.bmcl.2009.06.099)
- 10 Huang, S.; Lin, R.; Yu, Y.; Lu, Y.; Connolly, P.; Chiu, G.; Li, S.; Emanuel, S.; Middleton, S. *Bioorg. Med. Chem. Lett.* **2007**, *17*, 1243-1245.
DOI: [org/10.1016/j.bmcl.2006.12.031](https://doi.org/10.1016/j.bmcl.2006.12.031)
- 11 Witherington, J.; Bordas, V.; Gaiba, A.; Garton, N. S.; Naylor, A.; Rawlings, A. D.; Slingsby, B. P.; Smith, D. G.; Takle, A. K.; Ward, R. W. *Bioorg. Med. Chem. Lett.* **2003**, *13*, 3059-3062.
DOI: [org/10.1016/S0960-894X\(03\)00645-0](https://doi.org/10.1016/S0960-894X(03)00645-0) PMID: 12941333.
- 12 Saggat, S.; Sisko, J.; Tucker, T.; Tynebor, R.; Su, D.; Anthony, N. U.S. Patent Appl. US 2,007,021,442, 2007. *Chem. Abstr.*, **2007**, *146*, 163149.
- 13 De, K.; Bhaumik, A.; Banerjee, B.; Mukhopadhyay, C. *Tetrahedron Lett.* **2015**, *56*, 1614-1618.
DOI: [org/10.1016/j.tetlet.2015.01.163](https://doi.org/10.1016/j.tetlet.2015.01.163)
- 14 El-Sheref, E. M.; Aly, A. A.; Mourad, Aboul-Fetouh E; Brown, A. B.; Bräse, S.; Bakheet, M. E. M. *Chem. Papers* **2018**, *72*, 181-190.
DOI: [org/10.1007/s11696-017-0269-6](https://doi.org/10.1007/s11696-017-0269-6)
- 15 Aly, A. A.; El-Sheref, E. M.; Mourad, Aboul-Fetouh E; Brown, A. B.; Bräse, S.; Bakheet, M. E. M.; Nieger, M. *Monatsh. Chem.* **2018**, *149*, 635-644.
DOI: [org/10.1007/s00706-017-2078-6](https://doi.org/10.1007/s00706-017-2078-6)
- 16 Abdu-Allah H. H. M.; El-Emary T. I. *Der Pharma Chemica* **2016**, *8*, 9-16.
<http://derpharmachemica.com/archive.html>.
- 17 El-Emary T. I. *J. Chin. Chem. Soc.* **2007**, *54*, 507-518.
DOI: [org/10.1002/jccs.200700072](https://doi.org/10.1002/jccs.200700072)
- 18 El-Emary T. I., Hussein, A. M.; El-Kashef, H.S. *Pharmazie* **2000**, *55*, 356-358.
PMID: 11828614.
- 19 El-Emary, T. I. *J. Chin. Chem. Soc.* **1999**, *46*, 585-590.
DOI: [org/10.1002/jccs.199900080](https://doi.org/10.1002/jccs.199900080)
- 20 El-Emary, T. I.; Abd El-Mohsen, Sh. A. *Molecules* **2012**, *17*, 14464-14483.
DOI: [org/10.3390/molecules171214464](https://doi.org/10.3390/molecules171214464).
- 21 Abdelmohsen, S. A. ; El-Emary, T. I. Synthesis, *J. Adv. Chem.* **2014**, *10*, 2901-2915.
<https://pjournal.com/index.php/jac/article/view/6802>
- 22 Häufel, J.; Breitmaier, E. *Angew. Chem. Internat. Ed.* **1974**, *13*, 604-612.
DOI: [org/10.1002/anie.197406041](https://doi.org/10.1002/anie.197406041)
- 23 Ahluwalia, V. K.; Goyal, B. *Synth. Commun.* **1996**, *26*, 1341-1348.
DOI: [org/10.1080/00397919608003494](https://doi.org/10.1080/00397919608003494)

24. Sheldrick, G. M. *Acta Crystallogr.* **2015**, A71, 3-8.
DOI: [org/10.1107/S2053273314026370](https://doi.org/10.1107/S2053273314026370)
25. Sheldrick, G. M. *Acta Crystallogr.* **2015**, C71, 3-8.
DOI: [10.1107/S2053229614024218](https://doi.org/10.1107/S2053229614024218)
26. Spek, A. L. *Acta Cryst.* **2009**, D65, 148-155.
DOI: [org/10.1107/S090744490804362X](https://doi.org/10.1107/S090744490804362X)
27. Bräse, S.; Gil, C.; Knepper, K.; Zimmermann, V. *Angew. Chem.* **2005**, 117, 5320–5374; *Angew. Chem. Int. Ed.* **2005**, 44, 5188–5240.
DOI: 10.1002/anie.200400657 <https://onlinelibrary.wiley.com/doi/pdf/10.1002/anie.200400657>
28. Ghosh, A. K.; Sarkar, A.; Brindisi, M. *Org. Biomol Chem.* **2018**, 28; 2006-2027.
DOI: [10.1039/c8ob00138c](https://doi.org/10.1039/c8ob00138c).